Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Universal Health International Group Holding Limited (2211.HK)
Shenyang, CN
Operating as an investment holding company, Universal Health International Group Holding Limited specializes in the wholesale, retail, and distribution of a comprehensive range of pharmaceutical and healthcare products across China's northeastern region. Its extensive offerings span both Western and traditional Chinese medicines, including patent medicines, chemical preparations, antibiotics, biochemical and biological drugs, traditional Chinese medicine decoction pieces, protein assimilation preparations, peptide hormones, and blood products. The company also supplies medical equipment, disinfection products, nutritional and prepackaged foods, health care items, cosmetics, daily necessities, and specific consumer goods such as family planning supplies (e.g., contraceptives) and infant formula milk powder. Furthermore, Universal Health International Group Holding Limited provides storage services to its varied clientele, which includes pharmaceutical retailers, hospitals, clinics, and distributors. Founded in 1998, the enterprise was formerly known as Jintian Pharmaceutical Group Limited until its rebranding in July 2015, and its corporate headquarters are located in Shenyang, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.06% | -1.00% | -13.16% | -22.66% | -72.95% | -70.36% | -53.30% | +275.00% | +122.97% | -91.00% | -97.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-34.7% Q4'25: -54.9% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%-53,433.3% Q4'25: -97.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-2.1% Q4'25: +7.8% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-3.6% Q4'25: -1.3% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%-7.8% Q4'25: -4.4% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%-88.0% ★ Q4'25: -85.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-2.11× Q4'25: 4.96× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
|---|---|---|---|---|---|
| Revenue |
4.36B
est: 2.61B (+66.9%)
|
4.81B
est: 3.57B (+34.4%)
|
3.38B
est: 4.38B (-22.9%)
|
4.76B
est.
|
2.65B
est: 4.86B (-45.6%)
|
| EBITDA |
724.15M
est: -343.98M (+310.5%)
|
156.67M
est: 565.37M (-72.3%)
|
-11.34M
est: 670.58M (-101.7%)
|
177.17M
est.
|
-255.91M
est: -640.67M (+60.1%)
|
| EBIT |
687.61M
est: -425.75M (+261.5%)
|
113.00M
est: 567.00M (-80.1%)
|
-58.27M
est: 653.35M (-108.9%)
|
108.90M
est.
|
-300.58M
est: -792.96M (+62.1%)
|
| Net Income |
472.72M
est: 12.25M (+3,757.5%)
|
31.16M
est: 387.57M (-92.0%)
|
-87.81M
est: 456.66M (-119.2%)
|
34.92M
est.
|
-611.34M
|
| SGA |
592.13M
est: 740.84M (-20.1%)
|
1.13B
est: 453.71M (+150.1%)
|
818.82M
est: 572.01M (+43.1%)
|
1.27B
est.
|
734.87M
est: 1.38B (-46.7%)
|
| EPS |
2.38
est: 0.15 (+1,456.0%)
|
0.16
est: 0.19 (-15.1%)
|
-0.39
est: 0.20 (-297.8%)
|
—
est.
|
-2.24
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongkun Jin | Vice President & Executive Vice Chairman | 582.4K | male |
| Chuanfu Chu | Chief Executive Officer, Chief Operating Officer & Executive Chairman | 576.7K | male |
| Zehua Zhao | GM of Finance & Executive Director | 548.9K | male |
| Kit Ying Hui | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2211.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
